Study Helps Determine the Best Dosing Frequency of Triheptanoin for the Treatment of LCFAOD

A recent study by Wendy Putnam, PhD, from Ultragenyx developed a new model that could accurately estimate the elimination half-life of triheptanoin in patients with LCFAOD. This model can be used to calculate the best dosing frequency of triheptanoin marketed under the brand name Dojolvi® for the treatment of patients with LCFAOD

 

This LCFAOD research was originally published by Lee SK, Gosselin NH, Jomphe C, McKeever K, and Putnam W. in Population pharmacokinetics of heptanoate in healthy subjects and patients with long-chain fatty acid oxidation disorders treated with triheptanoin. Clin Pharmacol Drug Dev. Published online July 31, 2022.

Read the original article.